Thank you so much, Jon, and thank you all for joining us today. First, we are continuing to prioritize customer growth and ...

Earlier today, Hyperfine Inc. released financial results for the quarter ending December 31, 2025. Before we begin, I'd like ...

The investigators found that dd-cfDNA levels increased with histological evidence of graft inflammation, with the strongest associations observed in microvascular inflammation (MVI) and ...

Good morning, and welcome to the investor and analyst call for IG Group 2025 Results Presentation. [Operator Instructions] I would like to remind all participants that this call is being recorded. I ...

Study affirms superiority of iMDx GraftAssure assay’s proprietary dd-cfDNA combination model score: Nashville, Tennessee Monday, March 16, 2026, 18:00 Hrs [IST] Insight Molecula ...

UBS Global Consumer and Retail Conference March 11, 2026 1:00 PM EDTCompany ParticipantsHarmit Singh - Executive VP ...

As Asia’s population ages and healthcare demands rise, femtech is emerging as a mainstream growth opportunity Read more at The Business Times.

Irvine-based Tarsus Pharmaceuticals posted blockbuster Q4 and full year revenues driven by surging demand for its eyedrop ...

New data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary "Combination Model" score outperformed percentage-only measures of dd-cfDNARei ...

HeartBeam (Nasdaq:BEAT) announced today that it entered into a strategic collaboration with the Icahn School of Medicine at Mount Sinai.

Kostman noted, "The 2025 trimming of our supply and demand sources to ensure higher quality will impact our year-over-year comparisons early on," with soft year-over-year performance expected through ...

Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk ・Combines Mount Sinai’s world-class AI and ...